Camber adds Linezolid for Oral Suspension to portfolio
PISCATAWAY, N.J. – Camber Pharmaceuticals announces the addition of Linezolid for Oral Suspension to its current portfolio. Linezolid for Oral Suspension is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and resistant isolates) or Streptococcus pneumoniae. Linezolid for Oral Suspension is available in a 100 mg/5 mL strength and supplied in a 150 mL
